alirocumab vs rosuvastatin
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of alirocumab and rosuvastatin. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Praluent
Crestor
Praluent is a medicine that can lower cholesterol. It can also lower the risk of heart problems like heart attack or stroke in some adults.
Rosuvastatin is a drug that lowers cholesterol. It helps to reduce the risk of heart problems and stroke.
Praluent is used to lower LDL cholesterol (bad cholesterol). It is used along with diet and exercise in adults with high cholesterol. It is also used in adults and children 8 years and older who have a genetic condition that causes high cholesterol.
Rosuvastatin is used to lower bad cholesterol (LDL) in adults and children. It can also slow down the hardening of arteries in adults. This medicine also treats high triglycerides and certain inherited cholesterol disorders.
Praluent is a PCSK9 inhibitor. It works by blocking a protein in your body called PCSK9. Blocking this protein helps your body remove LDL cholesterol from your blood.
Rosuvastatin belongs to a class of drugs called statins. It works by blocking a substance your body needs to make cholesterol. This helps to lower your cholesterol levels.
- • Injection site reactions (redness, itching, swelling, pain)
- • Flu
- • Muscle pain
- • Diarrhea
- • Headache
- • Nausea
- • Muscle pain
- • Weakness
- • Constipation
- Myalgia 1,655
- Product Dose Omission 1,364
- Injection Site Pain 1,278
- Muscle Spasms 1,162
- Arthralgia 1,053
- Fatigue 11,700
- Nausea 10,039
- Dyspnoea 9,208
- Diarrhoea 9,198
- Myalgia 8,784
Serious allergic reactions have happened with Praluent, sometimes requiring hospitalization. If you have signs of a serious allergic reaction, stop using Praluent and get medical help right away.
Rosuvastatin can cause muscle problems, including muscle pain, tenderness, or weakness. Tell your doctor right away if you have these symptoms, especially if you also have a fever or feel sick. Rosuvastatin can also cause liver problems. Your doctor may do blood tests to check your liver before and during treatment.
There is not enough information about Praluent use during pregnancy to know if it is safe. If you are pregnant or plan to become pregnant, talk to your doctor before using Praluent.
Do not take rosuvastatin if you are pregnant. It can harm your unborn baby. Talk to your doctor about other ways to control your cholesterol during pregnancy. Breastfeeding is not recommended while taking rosuvastatin.
Also Compare, Nearby Drugs
Compare alirocumab with
Compare rosuvastatin with
How to Read This alirocumab vs rosuvastatin Comparison
alirocumab is classified in the PCSK9 Inhibitor drug class, while rosuvastatin sits within the HMG-CoA Reductase Inhibitor (Statin) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, alirocumab has 6,512 submissions while rosuvastatin has 48,929. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for alirocumab or rosuvastatin.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.